News

📰 $NVO ❖ NOVO NORDISK’S OZEMPIC CUTS RISK OF DEATH 20% IN KIDNEY TRIAL Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be… https://t.co/jlhi75N1Bj

May 24, 2024
Frank

$NVO

❖ NOVO NORDISK’S OZEMPIC CUTS RISK OF DEATH 20% IN KIDNEY TRIAL

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be… https://t.co/jlhi75N1Bj